A Randomized, Endoscopist-Blinded, Prospective Trial to Compare the Efficacy and Patient Tolerability between Bowel Preparation Protocols Using Sodium Picosulfate Magnesium Citrate and Polyethylene-Glycol (1 L and 2 L) for Colonoscopy
Table 1
Baseline characteristics.
Group A ()
Group B ()
Group C ()
value
Strict food restriction (no. (%))
25 (25.3%)
29 (29.3%)
22 (22.7%)
0.565
Age ( (years))
0.140
Height ( (m))
0.209
Weight ( (kg))
0.941
BMI ( (kg))
0.277
Comorbidities (no. (%))
Hypertension
31 (31.3%)
28 (28.3%)
32 (33.0%)
0.770
Diabetes mellitus
13 (13.1%)
12 (12.1%)
17 (17.5%)
0.517
Cardiovascular disease
10 (10.1%)
11 (11.1%)
8 (8.2%)
0.792
Others
33 (33.3%)
29 (29.3%)
25 (25.8%)
0.509
Indication for colonoscopy
Screening/surveillance
55 (56.1%)
50 (50.5%)
60 (61.9%)
0.278
History of colon polyp
22 (22.2%)
24 (24.2%)
20 (20.6%)
0.830
Abdominal pain
5 (5.1%)
10 (10.1%)
4 (4.1%)
0.184
Overt intestinal bleeding
1 (1.0%)
1 (1.0%)
2 (2.1%)
0.764
Occult blood in stool
1 (1.0%)
2 (2.0%)
1 (1.0%)
0.782
Loose stool
4 (4.0%)
2 (2.0%)
6 (6.2%)
0.336
Anemia
2 (2.0%)
2 (2.0%)
2 (2.1%)
1.000
Others
9 (9.0%)
8 (8.0%)
5 (5.2%)
0.855
Constipation
14 (14.1%)
16 (16.2%)
16 (16.3%)
0.895
Education (more than high school education)
69 (69.7%)
59 (59.6%)
64 (65.3%)
0.328
Currently single (unmarried/divorced/bereaved)
28 (28.3%)
33 (33.3%)
27 (27.6%)
0.626
Time interval from previous colonoscopy (years)
4.20
3.76
3.70
0.845
Group A: 2 L PEG-ASc; Group B: 1 L PEG-ASc plus bisacodyl; Group C: SP-MC plus bisacodyl; SD: standard deviation; BMI: body mass index. Constipation was defined as a defecation frequency of less than once every 3 days.
